WOBURN,
Mass., July 1, 2024 /PRNewswire/ -- Eirion
Therapeutics Inc. announced today that the first participant has
been enrolled in a Phase 1 clinical trial to evaluate the safety of
the patented topical pharmaceutical ET-02 for the treatment of
androgenic alopecia (age-related hair loss). This double-blind,
placebo-controlled study is designed to determine the safety of
ET-02 for once daily treatment over 28 days. The study is expected
to recruit approximately 24 subjects at three investigation centers
in the United States.
ET-02 has a novel mechanism of action which targets returning
hair follicle stem cells that have become defective and / or
inactive in men suffering from age-related hair loss to normal
activity and function. Hair follicle stem cells are known to be the
"master control switches" for hair growth. By returning stem cells
to normal activity and function, the expectation is that hair can
be grown normally again. Because ET-02 directly addresses what the
Company believes is the fundamental cause of androgenic alopecia,
the Company expects this new treatment has the potential to be
significantly more effective than existing treatments which have no
known direct impact on hair follicle stem cells.
"Given its postulated mechanism of action, ET-02 represents a
potentially substantial advancement over commercially available
pharmaceuticals for the treatment of androgenic alopecia," said
Jerry Shapiro, MD, a leading expert
on the treatment of hair loss and Professor of Dermatology at
New York University Grossman School of
Medicine. "This Phase 1 safety study is an important first step in
evaluating ET-02. Assuming all goes well, this study will lead to a
Phase 2 study evaluating ET-02's efficacy."
Jon Edelson, MD, CEO and
President of Eirion, added, "A controlled pre-clinical study of
ET-02 treating 90 human scalp tissue grafts from men who have
intermediate-stage androgenic alopecia demonstrates this
pharmaceutical's potential to restore hair growth and return hair
follicles to normal structure and function. Because of ET-02's
unique mechanism of action, we believe that ET-02 has the potential
to not only treat androgenic alopecia but prevent it."
Unlike some other commercially available treatments, ET-02 does
not target hormonal pathways and is not expected to have the side
effects associated with such treatments, which include sexual
dysfunction.
The Company believes that ET-02 also has the potential to treat
and prevent hair greying by impacting the stem cell that controls
hair color which is called the melanocyte stem cell. The Company
plans to pursue treatment of this indication in the future. ET-02
is the third product currently in development by Eirion. ET-01
topical neuromodulator is in Phase 2 and has been studied in
clinical trials with over 750 subjects in aggregate. AI-09
next-generation, ready-to-use liquid injectable neuromodulator has
been studied in 96 subjects in a Phase 1 - 2 clinical
trial.
"ET-02 is a highly complementary product to our two other
aesthetic bio-pharmaceutical products in development, which are
both potential treatments for facial wrinkles. Taking these three
product candidates together, Eirion has built an exciting and
robust pipeline for aesthetic medicine innovation," commented Dr.
Edelson.
About Eirion Therapeutics, Inc.
Eirion Therapeutics, Inc. is a privately held, clinical stage
biopharmaceutical company that is developing next-generation
prescription products for aesthetic dermatology. Eirion currently
has a rich pipeline of products focusing on treatments for
wrinkles, primary axillary hyperhidrosis, androgenic alopecia, and
hair greying. In the future, Eirion plans to pursue additional
indications that address other major unmet clinical needs for
physicians and their patients.
To learn more about Eirion, please visit:
www.eirionthera.com
Media Contact
Megan
Driscoll
EvolveMKD
mdriscoll@evolvemkd.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/eirion-therapeutics-announces-initiation-of-first-in-human-clinical-trial-evaluating-topical-et-02-for-the-treatment-of-androgenic-alopecia-302186429.html
SOURCE Eirion Therapeutics, Inc.